Business
Wanda and Dignity Health launch OncoVerse platform
Wanda and Dignity Health launch OncoVerse platform.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 3883Q NetScientific PLC 29 February 2016 \n\nNetScientific plc\n \nWanda™ partners with leading US Hospital Group Dignity Health™ to launch oncology decision support software platform - OncoVerse™ \nLondon, UK - 29 February 2016 - NetScientific plc (\"NetScientific\" or the \"Group\", AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that its operating subsidiary, Wanda, has signed a collaborative deal with one of the US's biggest hospital groups, Dignity Health, to launch OncoVerse, a digital health oncology care platform. \nOncoVerse is a software platform designed to enable a patient's care team to collaborate in real-time, allowing clinicians across all disciplines to work together to determine the most effective treatment plan for cancer patients. Dignity Health engaged Wanda to develop the software due to the Company's proven track record in developing effective platforms that support informed treatment decisions. The software will also help to reduce administrative costs associated with high quality cancer care.\n \nDignity Health is a network of nearly 9,000 physicians and more than 400 care centers, including hospitals and primary care clinics spanning 21 US states. The OncoVerse platform will support Dignity Health's physicians and healthcare professionals to enable them to make informed decisions on the treatment of cancer patients. It will also enable Dignity Health to expand the geographic reach of its clinical decision-making support system to reach the most rural and remote areas - allowing all patients to benefit from insights previously only shared at large medical centers. \n \nWanda and Dignity Health are shareholders in Oncoverse LLC, a San Francisco based digital health company, and the creator of the OncoVerseTM software platform. Wanda and Dignity Health will jointly market the Oncoverse platform to other oncology programs across the US later in 2016 to earn revenues through uptake of the platform. The relationship with Dignity Health will also allow for cross-marketing of existing and future Wanda products.\n \nFacilitating individualized cancer decision support is becoming increasingly important as cancer therapies advance. Wanda's core technology aims to improve the efficiency and effectiveness of the management of ...